Prerpints.org logo
Preprint
Article

Switch/Sucrose Non-fermentable (SWI/SNF) Complex-Partial Loss in Sinonasal Squamous Cell Carcinoma. Impact in the Morphology and Prognosis

Altmetrics

Downloads

85

Views

50

Comments

0

supplementary.pdf (144.08KB )

Submitted:

28 August 2024

Posted:

29 August 2024

You are already at the latest version

Alerts
Abstract
Sinonasal carcinomas are aggressive neoplasms that present a high morbidity and mortality rate with unfavorable prognosis. This group of tumors exhibits morphological and genetic diversity. Genetic and epigenetic alterations in these neoplasms are currently targets for diagnosis and treatment. The most common type of cancer originated in the sinonasal tract are sinonasal squa-mous cell carcinomas (SNSCC), which presents different histological patterns and variable his-tological aggressiveness. A significant number of alterations have been reported in sinonasal tu-mors, including deficiencies in the SwItch/Sucrose non-fermentable (SWI/SNF) chromatin remod-eling complex. In the sinonasal tract, deficiencies of the subunits SMARCB1/INI1, SMAR-CA4/BRG1 and SMARCA2 have been noted in carcinomas, adenocarcinomas, and soft tissue tu-mors with distinctive high-grade morphology and fatal prognosis. Objective: To identify the status of the SWI/SNF complex using immunohistochemistry in sinonasal squamous cell carci-nomas and its association with morphology and survival. Methods: A total of 1582 SNSCC cases were analyzed, selecting those with high-grade malignancy morphology, which were then evalu-ated immunohistochemically for SMARCB1 and SMARCA4 proteins. Their expression was compared with the biological behavior and survival of the patients. Results: Among the SNSCC, 47% corresponded to the non-keratinizing squamous cell carcinoma (NKSCC) type with high-grade characteristics, 40% were keratinizing squamous cell carcinomas (KSCC), 9% were SMARCB1-deficient carcinomas, and 4% were SMARCA4-deficient carcinomas. Mosaic expres-sion for SMARCB1 (NKSCC 33%, KSCC 21.9%) and SMARCA4 (NKSCC 14.6%, KSCC 12.2%) was identified, showing an impact on tumor size and progression. Conclusions: We identified that the mosaic expression of INI1 in NKSCC exhibited a worse prognosis compared to intact carcinomas and was similar to SMARCB1-deficent carcinoma.
Keywords: 
Subject: Medicine and Pharmacology  -   Pathology and Pathobiology

1. Introduction

The multiprotein Switch/Sucrose-Non-Fermentable (SWI/SNF) complex, also known as BAF (BRG1-associated factors), in mammals consists of more than 20 subunits that vary by tissue type and embryonic stage. This complex plays a crucial role in gene expression and transcription regulation. [1,2]. Deficiencies in specific core proteins required for the assembly of certain SWI/SNF subunits have been reported in different types of cancers, affecting multiple organs such as the lungs, genitourinary tract, gastrointestinal tract, central nervous system, and head and neck. The SWI/SNF chromatin remodeling complexes are responsible for the proper positioning of nucleosomes SWI/SNF complexes belong to three subfamilies: canonical BAF (cBAF), GLTSCR1 and GBAF-complexes, and polybromo-associated BAF (PBAF) [1,2].
Recently, a subset of carcinomas originating in the sinonasal tract has been identified with distinct biological aggressiveness, characterized by the complete loss of SWI/SNF complex subunits, particularly SMARCB1 (INI1) and SMARCA4 (BRG1) / SAMRCA2. [3,4]. Sinonasal carcinomas represent the 4% of all malignant neoplasms affecting the head and neck, with the most common originating in the nasal cavity and paranasal sinuses [5]. SWI/SNF complex-deficient carcinomas are rare. However, this group includes carcinomas and adenocarcinomas that completely lose the expression of certain subunits of the complex [6]. In surgical pathology practice, the evaluation of the SWI/SNF complex has become a useful tool for the diagnosis and classification of neoplasms with altered expression of complex-subunits. In head and neck cancers, recent descriptions include neoplasms with deficiencies in certain subunits of the SWI/SNF complex, such as malignant rhabdoid tumors, head and neck epithelioid sarcoma, SMARCB1-deficient sinonasal carcinoma, SMARCB1-deficient sinonasal adenocarcinoma, SMARCA4-deficient sinonasal carcinoma, and SMARCA4-deficient sinonasal teratocarcinosarcoma [6].
Sinonasal squamous cell carcinoma (SNSCC) is the most frequent carcinoma that develops in the nasal cavity and paranasal sinuses. Its pathogenesis has been associated with exposure to wood dust, construction material particles, high-risk HPV infections, and precursor lesions such as sinonasal inverted papilloma particularly the oncocytic variant [7].
SNSCCs are classified into two variants based on their histologic features and keratinization capacity. Keratinizing or conventional squamous cell carcinoma (KSSC) is characterized by aggressive squamous differentiation with evident keratin deposits and diversity of growth patterns, including papillary, adenosquamous, basaloid, sarcomatoid, and acantholytic. Non-keratinizing squamous cell carcinoma (NKSSC) presents with a basaloid morphology, in absence or focal keratinization with a consistent transitional-type growth pattern. Sinonasal SCCs are associated with high morbidity and mortality due to their tendency to extend to the oral cavity, orbit, skull base, and facial deformity, as well as their potential to generate distant metastases [8,9].
Total or partial loss of expression of SWI/SNF-complex subunits results from the inactivation of this chromatin remodeling complex, contributing to increased cytological aggressiveness and a poor prognosis in neoplasms [10]. Assessing the SWI/SNF chromatin remodeling complex has facilitated the classification and development of therapeutic strategies for various soft tissue tumors, carcinomas, and adenocarcinomas affecting organs such as the lungs, genitourinary tract, gastrointestinal tract, central nervous system, nasal cavity, and paranasal sinuses [3,4,11]. Immunohistochemical analysis has proven instrumental in demonstrating the total or partial loss of SMARCB1 (INI1) and SMARCA4 (BRG1) subunits, making it a valuable tool for diagnosis and therapeutic decision-making [12].
This study examines the expression of the SWI/SNF complex and its impact on the biological behavior of poorly differentiated or high-grade squamous carcinomas originating in the sinonasal tract. Through immunohistochemical analysis, we identified the inactivation or partial loss (mosaic expression) of SMARCB1 and SMARCA4 subunits, correlating with disease morphology and progression. These findings pave the way for future research to expand therapeutic options and refine the classification of this neoplasm.

2. Materials and Methods

2.1. Sample Selection

All cases diagnosed as sinonasal tract carcinomas at INCan (National Cancer Institute of Mexico) were reviewed to identify and select squamous cell carcinomas and poorly differentiated carcinomas originating in the nasal cavity and paranasal sinuses, during the period from January 2006 to December 2018. Out of a total of 1,582 cases of carcinomas originated in the sinonasal tract recorded over a 12-year period, only 103 were selected for inclusion in the study. The variables considered for the inclusion of samples were gender, age, tumor epicenter location, tumor size, histological diagnosis, presence of metastasis, oncological stage, and time elapsed from diagnosis to death or recurrence.

2.2. Morphologic Analysis and Tissue Microarray (TMA)

The available histological material for each case was reviewed with the aim of confirming the correct histological classification of the samples according to diagnostic criteria (5). Three study groups were identified: NKSCC (n=48), KSCC (n=41), and Basaloid / Poorly Differentiated Carcinomas (n=14). The histological parameters evaluated in all groups included: cytological morphology, growth pattern, presence of desmoplasia, neural and vascular infiltration, type and disposition of the inflammatory infiltrate, and necrosis. For the poorly differentiated carcinoma group, negativity was confirmed for neuroendocrine, neuroectodermal markers, NUT-1, MDM2, and their association with HPV and EBV.
Detailed histological analysis for each case was focused in selecting tumor areas with basaloid or high-grade characteristics, that were distanced from inflammation, hemorrhage, or necrosis, to avoid alterations in immunohistochemical assay expression. The concordance index (Fleiss’ Kappa 0.98) was obtained through interobserver measurements for each of the carcinoma groups analyzed.
Microarrays of tissue (TMA) were then prepared following an established method (13). Briefly, this technique involves creating an adhesive grid pre-sized to fit the histological embedding mold. Using a 3mm diameter “punch” biopsy instrument, tissue cylinders were extracted from the donor block and directly inserted onto the adhesive surface of the grid. Once the cylinders were arranged, they were immersed in a mold with molten paraffin at 70°C until completely covered. The paraffin block containing the TMA was allowed to cool at -3°C for 15 min. After the paraffin solidified, the grid was removed, and blocks were obtained from which 5-micron sections were cut for evaluation with hematoxylin and eosin staining.
The pathological parameters assessed in the SNSCC samples included: histological subtype, pattern of invasion, presence of basaloid, rhabdoid, or plasmacytoid cytomorphology of tumor cells, vascular and neural invasion, tumor size, and extension to adjacent anatomical structures.

2.3. Immunohistochemical Assay for SWI/SNF-Subunits Complex Evaluation

Immunohistochemical assays for SMARCB1 (clone MRQ27, Cell Marque, Rocklin, CA; dilution 1:100) and SMARCA4 (clone BSB-154, BioSB, Santa Barbara, CA; prediluted) were performed on 5-micron thick sections, following the standardized protocol by Ventana Benchmark XT autostainer.
Two methods were employed for result analysis. The first method utilized was the semi-quantitative Allred scale (14), which assesses both the intensity and percentage of positive cells in the sample. This scale consists of 8 points, derived from the sum of 6 ranges for positive cell counts (0 to 5) and 4 ranges for intensity (0 to 3). For our study, the samples were categorized into three groups based on the expression levels of SMARCB1/INI1 and SMARCA4/BRG1 according to the Allred score: expression levels between 0-2 were classified as “deficient,” scores of 3-5 as “partial loss or mosaic expression,” and scores of 6-8 as “intact” (Figure S1, Supplementary Material). The second method involved a quantitative analysis of the immunohistochemistry results using ImageJ® software (15) (NIH, Bethesda, MD, USA). This analysis was performed on 5 photomicrographs at 400x magnification for each case, using the LEICA DM500 microscope equipped with the LEICA ICC50 W camera. Following software calibration, optical density (OpDe) measurements were taken to quantify the loss of SMARCB1 and SMARCA4 expression across 4 groups: absent (loss) 0-0.9, mild expression 1-1.9, moderate expression 2-2.9, and intense expression >3 OpDe. For interpretation, 200 cells per photomicrograph were quantified to obtain the average optical density.

2.4. Follow up and Survival Analysis of SWI/SNF-Partial Inactivation in Sinonasal Squamous Cell Carcinoma

Survival analysis was conducted using SPSS software. The association between partial loss of SWI/SNF complex subunits INI1/SMARCB1 and BRG1/SMARCA4 and time to death was evaluated using the Chi-square test. Survival analysis was further performed using the Kaplan-Meier method and the log-rank test. A p-value of <0.05 was considered statistically significant.

3. Results

3.1. Squamous Cell Carcinoma with High-Grade Morphology in the Paranasal Sinuses and Nasal Cavity

A total of 1,581 cases of sinonasal carcinomas (SNC) collected over a 12-year period were analyzed. Only 6.5% (n=103) were classified as high-grade squamous cell carcinomas, characterized by basaloid, plasmacytoid, or anaplastic cellular features (Figure 1 D,E). The distribution by gender revealed a higher incidence in males (59%) compared to females (41%) (Table 1). The age of presentation ranged from the second to the eighth decade of life, with a mean age of 54.1 years. High-grade sinonasal squamous cell carcinoma (NKSCC) was present in 47% of the cases (n=48) (Figure 1 D), while high-grade keratinizing squamous cell carcinoma (KSCC) represented 40% (n=41) (Figure 1 E). Nine cases exhibited loss of SMARCB1 expression (Figure 1 F), and 4% (n=5) showed loss of SMARCA4 expression (Figure 1 C). The average tumor size for both squamous cell carcinoma groups was 7 cm (Figure 1 A,B). Squamous cell carcinomas demonstrated a higher frequency of local invasion and locoregional lymphatic metastasis. The survival for the NKSCC group was 18.3 ± 16.08 months, while the KSCC group had a survival of 16.95 ± 17.04 months.
Preprints 116512 i001

3.2. Partial Loss (Mosaic) of INI1/SMARCB1 in Sinonasal Non-Keratinizing Squamous Cell Carcinoma

Of the 48 sinonasal non-keratinizing squamous cell carcinoma (NKSCC) cases analyzed, 33.3% (n=16) exhibited a mosaic expression pattern for INI1/SMARCB1. The loss of expression was particularly evident in high-grade tumor areas (Figure 2 A). Cells lacking expression alternated with cells showing intact expression, thus the pattern was classified as “mosaic expression” (Figure 2 C).
Patients with partial loss of INI1 were predominantly male (56%) and female (44%), with a mean age of 48 ± 18.4 years. Tumor size averaged 5.0 ± 1.4 cm. The most affected anatomical site was the maxillary sinus (62.5%, n=10), followed by the nasal cavity (25%, n=4) and the ethmoid sinus (12.5%, n=2). Notably, 90% of the cases demonstrated invasion into adjacent anatomical structures and regional lymphatic metastasis, while 10% exhibited multiorgan metastasis (CNS and lung). At diagnosis, 75% of the cases were staged as IV (n=12), and 25% as stage III (n=4) (Table 2).

3.3. Partial Loss (Mosaic) of BRG1/SMARCA4 in Sinonasal Non-Keratinizing Squamous Cell Carcinoma

Among the 48 cases in the NKSCC group, 14% (n=7) exhibited a decrease in BRG1/SMARCA4 expression. SMARCA4 showed partial mosaic inactivation, particularly in the anaplastic areas of the tumor located at the invasion front (Figure 3 D). Partial inactivation of SMARCA4 was more prevalent in males, comprising 57% (n=4) of cases, compared to 43% (n=3) in females. The average age was 48 ± 18.4 years, and the mean tumor size was 5 ± 1.5 cm. The most common primary tumor site was the maxillary sinus (57%, n=4), followed by equal involvement of the nasal cavity, ethmoid sinuses, and frontal sinus, with one case (14.3%) each. In this group, 43% (n=3) of carcinomas invaded adjacent structures such as the paranasal sinuses, orbit, and skull base. Three cases (43%) presented locoregional lymphatic and distant metastasis to the CNS and lung. Only one case (14%) showed isolated lymphatic metastasis. At the time of diagnosis, the oncologic staging of the patients was III and IV, with 29% (n=2) in stage III and 71% (n=5) in stage IV (Table 2).
Preprints 116512 i002

3.4. Partial Loss (Mosaic) of INI1/SMARCB1 in Sinonasal Keratinizing Squamous Cell Carcinoma

Of the 41 KSCC cases analyzed, 21% (n=9) exhibited a mosaic expression pattern for INI1/SMARCB1. Loss of expression was particularly evident in basaloid cells with scant cytoplasm. The mosaic expression appeared in areas with limited keratin formation and primitive cytomorphology (Figure 3 B, E). Partial inactivation of INI1 was slightly more prevalent in men, comprising 55% (n=5) of cases, compared to 45% (n=4) in women. The average age was 51 ± 11.5 years, with a mean tumor size of 7.8 ± 5.8 cm. The most affected anatomical site was the maxillary sinus (77.8%, n=7), followed by the nasal cavity (11.1%, n=1) and ethmoid sinus (11.1%, n=1). In terms of metastasis, 44.4% (n=4) of the cases showed lymph node involvement, while 44.4% (n=4) had local invasion into adjacent anatomical structures such as the oral cavity and orbit. Only one case (11.1%) demonstrated metastasis to the C3 cervical vertebra. At the time of diagnosis, 55.6% (n=5) of patients were in stage III, while 44.4% (n=4) were diagnosed at stage IV (Table 2).

3.5. Partial Loss (Mosaic) of BRG1/SMARCA4 in Sinonasal Keratinizing Squamous Cell Carcinoma

Of the 41 KSCC cases, 12.5% (n=5) exhibited reduced expression of BRG1/SMARCA4. Partial inactivation of BRG1 was identified as mosaic expression in areas with higher histological aggressiveness and at the tumor invasion front (Figure 3 F). In this group of carcinomas, partial inactivation of SMARCA4 was more prevalent in women (60%, n=3) than in men (40%, n=2). The average age of presentation was 61 ± 15.3 years, with a mean tumor size of 5.8 ± 2.4 cm. The most affected anatomical locations were the nasal cavity and maxillary sinus, each representing 40% (n=2) of the cases. The frontal sinus was affected in one case, accounting for 20% of the carcinomas with altered BRG1 expression. Locoregional lymph node metastases were observed in 40% (n=2) of the cases. Another 40% presented locoregional lymph node metastasis with invasion into other structures—one case extending into the orbit and another into the skull base with meningeal extension. Only one case (20%) presented regional lymph node metastasis with distant spread to the lumbar vertebrae (Table 2).

3.6. Survival Analysis of SNSCC with Partial Inactivation of SMARCB1 and SMARCA4

Overall survival was calculated using the Kaplan-Meier method, with differences in survival between mosaic and intact expression with the log-rank test, considering a p≤0.05 as statistically significant. The mean of survival was 18.3 ± 16.05 months for the NKSCC group, and 16.9 ± 17.04 months for the KSCC group. From the 48 NKSCC cases, only 4 were registered alive and disease-free at the 5-year follow-up. The remaining patients died due to tumor-related causes. In contrast to the KSCC group, only 6 out of 41 cases were alive and disease-free at 5 years of follow-up. The mean of survival for the NKSCC with partial loss of SMARCB1 and SMARCA4 was 13.3 ± 1.9 and 18.3 ± 3.7 months respectively. For the KSCC group with partial loss of SMARCB1 and SMARCA4, the mean survival was 22.3 ± 6 and 16.5 ± 3.8 months, respectively. In our tumor-adjusted model, NKSCC showed an increased risk with the presence of SMARCB1 mosaic expression (HR=2.96, 95% CI=9.53-17.09, p=0.085), with a median survival of 13.31 months, compared to 25.0 months for intact expression (Figure 3A). NKSCC with partial loss of SMARCA4 (HR=0.007, p=0.93) (Figure 3B), KSCC with partial loss of SMARCB1 (HR=1.0, p=0.31) (Figure 3C), and KSCC with partial loss of SMARCA4 (HR=0.20, p=0.65) (Figure 3D) did not show statistically significant differences in survival.

4. Discussion

Sinonasal carcinomas are a group of tumors with locally aggressive behavior and unfavorable prognosis due to their high rate of recurrence and progression and capacity to generate metastases [5]. The genomic and epigenetic characterization of these tumors has allowed a more precise classification [5,16].
The WHO classifies carcinomas originating in the paranasal sinuses, nasal cavity, and the skull base based on their histological appearance and genetic alterations into different groups: squamous cell carcinomas, lymphoepithelial carcinoma, HR HPV-related carcinomas (multiphase and monophase), NUT rearranged carcinomas, undifferentiated carcinomas (SNUC), neuroendocrine carcinomas, adenocarcinomas, and SWI/SNF complex-deficient carcinomas [16,17].
Squamous cell carcinomas originating in the sinonasal tract are rare neoplasms with a high rate of progression. Risk factors for the development of these neoplasms include chronic exposure to wood dust, industrial materials, smoking, human papillomavirus infections and oncocytic sinonasal papillomas. [5,7] In our study, SNSCCs accounted for 64% of all tumors that developed in the sinonasal tract over a 12-year period, consistent with previous reports [7,18]. We found that some patients with SNSCC exhibited risk factors such as high-risk HPV exposure, exposure to wood smoke, and industrial materials [18,19].
Inadequate functioning or inactivation of the SWI/SNF complex can lead to distinctive cellular morphological changes such as rhabdoid and plasmacytoid morphology, large anaplastic cells, or small round cells in various soft tissue neoplasms and carcinomas affecting multiple organs [2,25]. A wide variety of benign and malignant tumors with alterations in several genes belonging to the SWI/SNF complex have been described, including SMARCB1, SMARCA4, SMARCA2, and ARID1A. These related tumors affect a range of tissues, primarily including epithelial, meningeal, glioneural, hematologic, and lymphoid tissues [26].
SMARCB1 (INI1)-deficient sinonasal carcinomas represent a group of poorly differentiated carcinomas characterized by the loss or complete inactivation of the SMARCB1 subunit, resulting in a basal-like, anaplastic, and even rhabdoid morphology. In our study, we identified 9 SMARCB1-deficient carcinomas, of which 77% were men and 23% were women, a similar distribution to previous case series reported [28]. The aggressiveness of this type of tumor was measured based on the high mortality rate with a median survival of 5 months after diagnosis in our cases. Additionally, there was a high frequency of locoregional disease and distant organ involvement, consistent with previously reported findings [28].
In addition to the “loss of expression” due to complete genetic inactivation of the SWI/SNF-complex subunits, a pattern of partial expression or “mosaic expression” has been recognized in conditions such as schwannomatosis and tumors such as gastrointestinal stromal tumors and ossifying fibromyxoid tumors [29,30]. However, there are no reports of mosaic expression or partial inactivation of the SWI/SNF complex in carcinomas affecting the sinonasal tract. Absence of SMARCB1 and SMARCA4 in neoplasms, exhibit a complete loss of expression assessed by immunohistochemistry [30,31].
In this study, we focused in sinonasal squamous cell carcinoma (SNSCC) for several reasons: 1) It is the most common type of tumor that develops in the paranasal sinuses and nasal cavity, 2) it has a broad morphological spectrum; despite being classified into two histological subgroups (keratinizing and non-keratinizing), it can exhibit a variety of growth patterns such as papillary, basal-like, exophytic, infiltrative, acantholytic, and sarcomatoid (spindle cells), and 3) its morphological heterogeneity also results from a wide range of processes, pathways, and molecular alterations involved in its origin and progression, making it susceptible to various genetic and transcriptional alterations that influence its biological behavior and prognosis [31,32].
We included a total of 89 SNSCCs with high-grade morphological characteristics, where 33% of the NKSCCs and 21.9% of the KSCCs exhibited mosaic expression for INI1. When evaluating pathological features and follow-up, differences were identified between carcinomas with intact expression and those that were deficient. One notable parameter was the average tumor size, which was similar between both groups with an average of 5 cm, compared to the 7 cm average reported for SMARCB1-deficient carcinomas [28]. Kaplan-Meier survival analysis showed a relationship between SMARCB1 mosaic expression in NKSCCs and prognosis, with a more unfavorable outcome compared to KSCCs with mosaic expression (INI1 SCC mosaic expression HR=2.9, p=0.085).
Deficiency in the SMARCA4 subunit has been described in rare malignant neoplasms with poor prognosis, such as small cell carcinoma of the ovary, hypercalcemia type (SCCOHT), some thoracic carcinomas, gastrointestinal and genitourinary tract carcinomas, as well as non-small cell lung carcinoma [34]. In the sinonasal tract, primarily two neoplasms deficient in SMARCA4 have been reported: SMARCA4-deficient sinonasal carcinoma and SMARCA4-deficient sinonasal teratocarcinosarcoma. [6,33,34,35]. In the present study, we analyzed the SMARCA4 status in SNSCC, finding mosaic expression in 14% of high-grade malignancy SN-NKSCC and in 12% of keratinizing SNSCC.
Comparing the mosaic expression of SMARCA4 versus SMARCB1, we observed a difference in the intensity of expression: the mosaic immunohistochemical reaction for SMARCB1 was intense in the intact cells and completely absent in SMARCB1-deficient cells as expected, whereas SMARCA4-mosaic expression showed a gradual loss of expression from intensely positive (SMARCA4-intact cells) to those cells with complete absence “loss” of expression. This suggests that the inactivation of these two complex subunits occurs in a gradual process which impacts in morphology during the cell dedifferentiation process.
SMARCA4-deficient sinonasal carcinomas are a type of poorly differentiated or undifferentiated tumors, locally very aggressive and with a poor short-term prognosis, characteristics shared with sinonasal undifferentiated carcinoma (SNUC). One distinguishing difference between this group of lethal carcinomas and SMARCA4-deficient sinonasal carcinomas is IDH2 mutation [36,37,38].
Mosaic expression of SMARCA4 has not been reported in tumors as extensively as mosaic expression of SMARCB1. This study offers an opportunity to assess its impact on other neoplasms in the sinonasal tract or other organs with potential SWI/SNF complex alterations. Current genetic studies and clinical trials are increasingly focused on identifying targets for classification, risk assessment, and therapeutic strategies, particularly in high-morbidity and mortality neoplasms like sinonasal carcinomas [39,40]. We believe the findings presented in this study significantly contribute to the understanding of sinonasal carcinomas with SWI/SNF complex alterations. Furthermore, our results may pave the way for future studies that explore the diagnostic and prognostic value of SMARCB1 and SMARCA4 mosaic expression in classification and therapeutic planning.

5. Conclusions

Sinonasal carcinomas originated in the sinonasal tract are a heterogeneous group of tumors with diverse morphology and genetic defects impacting poor prognosis. SWI/SNF complex-deficient sinonasal carcinomas are now well-recognized as high-grade malignancies with distinctive deficiencies in the SMARCB1 and SMARCA4 subunits, distinguishing them from other poorly differentiated neoplasms such as SNUC or poorly differentiated carcinomas. Mosaic expression of SMARCB1 has been reported in soft tissue tumors as a diagnostic tool and a parameter of morphological aggressiveness. We concluded that partial loss (mosaic expression) of SMARCB1 and SMARCA4 in SNSCC is associated with high-grade malignant characteristics and a negative effect on patient survival.

Supplementary Materials

The following supporting information can be downloaded at the website of this paper posted on Preprints.org. Figure S1: Immunohistochemical staining for SWI/SNF-complex evaluation.

Author Contributions

Conceptualization, R.O.C.-T., A.M.C.-V. and J.P.-R.; methodology, R.O.C.T., J.P.R. L.C.-A. and A.M.G.; data base; R.O.C.-T., A.M.C.-V. histological analysis, R.O.C.-T., A.M.C.-V.; immunohistochemical analysis, R.O.C.-T., A.M.C.-V., A.M.-F and D.B.S-; resources, J-P.-R., and A.M.-G; data curation, R.O.C.-T., and L.C.-A; writing—original draft preparation, R.O.C.T.; writing—review and editing, A.M.C-V., G.V-O. and J.P.-R.; visualization, A.M-F, D.B-S., and G.V.-O; supervision, J-P.-R., A.M.C.-V. and A.M.-G.; project administration, J.P.-R., and R.O.C.-T.; funding acquisition, J-P.-R., and A.M.-G. All authors have read and agreed to the published version of the manuscript.

Funding

This research received no external funding.

Institutional Review Board Statement

The study was conducted in accordance with the Declaration of Helsinki, and approved by the Institutional Review Board of National Institute of Cancer México.

Informed Consent Statement

Not applicable.

Acknowledgments

We thank data acquisition and the Immunohistochemical Department of the National Institute of Cancer Mexico, and CONAHCYT CVU:643347.

Conflicts of Interest

The authors declare no conflicts of interest.

References

  1. Mittal, P.; Roberts, C.W.M. The SWI/SNF complex in cancer — biology, biomarkers and therapy. Nat. Rev. Clin. Oncol. 2020, 17, 435–448. [Google Scholar] [CrossRef] [PubMed]
  2. Schaefer, I.-M.; Hornick, J.L. SWI/SNF complex-deficient soft tissue neoplasms: An update. Semin. Diagn. Pathol. 2020, 38, 222–231. [Google Scholar] [CrossRef] [PubMed]
  3. Agaimy, A.; Foulkes, W.D. Hereditary SWI/SNF complex deficiency syndromes. Semin. Diagn. Pathol. 2018, 35, 193–198. [Google Scholar] [CrossRef]
  4. Tessier-Cloutier, B.; Kleinman, C.L.; Foulkes, W.D. SWI/SNF-deficient undifferentiated malignancies: where to draw the line†. J. Pathol. 2021, 256, 139–142. [Google Scholar] [CrossRef]
  5. Thompson, L.D.R.; Bishop, J.A. Update from the 5th Edition of the World Health Organization Classification of Head and Neck Tumors: Nasal Cavity, Paranasal Sinuses and Skull Base. Head Neck Pathol. 2022, 16, 1–18. [Google Scholar] [CrossRef]
  6. Agaimy, A.; Bishop, J.A. SWI/SNF-deficient head and neck neoplasms: An overview. Semin. Diagn. Pathol. 2021, 38, 175–182. [Google Scholar] [CrossRef] [PubMed]
  7. Bishop, J.A. OSPs and ESPs and ISPs, Oh My! An Update on Sinonasal (Schneiderian) Papillomas. Head Neck Pathol. 2017, 11, 269–277. [Google Scholar] [CrossRef] [PubMed]
  8. Turner, J.H.; Reh, D.D. Incidence and survival in patients with sinonasal cancer: A historical analysis of population-based data. Head Neck 2011, 34, 877–885. [Google Scholar] [CrossRef] [PubMed]
  9. Haas, M.B.; Hansen, E.E.M.; Lewis, J.S.J.; Faden, D.L.M. Is it Time for a Molecular-based Classification System for Sinonasal Squamous Cell Carcinoma? Am. J. Surg. Pathol. 2022, 46, 873–877. [Google Scholar] [CrossRef]
  10. Agaimy, A. The Expanding Family of SMARCB1(INI1)-deficient Neoplasia. Adv. Anat. Pathol. 2014, 21, 394–410. [Google Scholar] [CrossRef]
  11. Lechner, M.; Liu, J.; Lund, V.J. Novel Biomarkers in Sinonasal Cancers: from Bench to Bedside. Curr. Oncol. Rep. 2020, 22, 1–10. [Google Scholar] [CrossRef] [PubMed]
  12. Agaimy, A. Proceedings of the North American Society of Head and Neck Pathology, Los Angeles, CA, March 20, 2022: SWI/SNF-deficient Sinonasal Neoplasms: An Overview. Head Neck Pathol. 2022, 16, 168–178. [Google Scholar] [CrossRef] [PubMed]
  13. Chen, N.; Zhou, Q. Constructing Tissue Microarrays Without Prefabricating Recipient Blocks. Am. J. Clin. Pathol. 2005, 124, 103–107. [Google Scholar] [CrossRef] [PubMed]
  14. Allred, D.C.; Harvey, J.M.; Berardo, M.; Clark, G. Prognostic and predictive factors in breast cancer by inmunohistochemical analysis. Mod. Pathol. 1998, 11, 159. [Google Scholar]
  15. de Matos, L.L.; Stabenow, E.; Tavares, M.R.; Ferraz, A.R.; Capelozzi, V.L.; Pinhal, M.A.d.S. IMMUNOHISTOCHEMISTRY QUANTIFICATION BY A DIGITAL COMPUTER-ASSISTED METHOD COMPARED TO SEMIQUANTITATIVE ANALYSIS. Clinics 2006, 61, 417–424. [Google Scholar] [CrossRef]
  16. Hermsen, M.A.; Bossi, P.; Franchi, A.; Lechner, M. Sinonasal Cancer: Improving Classification, Stratification and Therapeutic Options. Cancers 2023, 15, 1675. [Google Scholar] [CrossRef]
  17. Agarwal, A.; Bhatt, A.; Bathla, G.; Kanekar, S.; Soni, N.; Murray, J.; Vijay, K.; Vibhute, P.; Rhyner, P. Update from the 5th Edition of the WHO Classification of Nasal, Paranasal, and Skull Base Tumors: Imaging Overview with Histopathologic and Genetic Correlation. Am. J. Neuroradiol. 2023, 44, 1116–1125. [Google Scholar] [CrossRef]
  18. Carrillo, J.; Güemes, A.; Ramírez-Ortega, M.; Oñate-Ocaña, L. Prognostic factors in maxillary sinus and nasal cavity carcinoma. Eur. J. Surg. Oncol. (EJSO) 2005, 31, 1206–1212. [Google Scholar] [CrossRef]
  19. López, F.; Inclán, C.G.; Pérez-Escuredo, J.; Marcos, C.; Scola, B.; Suárez, C.; Llorente, J.L.; Hermsen, M.A. KRAS and BRAF mutations in sinonasal cancer. Oral Oncol. 2012, 48, 692–697. [Google Scholar] [CrossRef]
  20. Al-Qurayshi, Z.; Smith, R.; Walsh, J.E. Sinonasal Squamous Cell Carcinoma Presentation and Outcome: A National Perspective. Ann. Otol. Rhinol. Laryngol. 2020, 129, 1049–1055. [Google Scholar] [CrossRef]
  21. Taverna, C.; Agaimy, A.; Franchi, A. Towards a Molecular Classification of Sinonasal Carcinomas: Clinical Implications and Opportunities. Cancers 2022, 14, 1463. [Google Scholar] [CrossRef] [PubMed]
  22. Pacini, L.; Cabal, V.N.; Hermsen, M.A.; Huang, P.H. EGFR Exon 20 Insertion Mutations in Sinonasal Squamous Cell Carcinoma. Cancers 2022, 14, 394. [Google Scholar] [CrossRef] [PubMed]
  23. Rooper, L.M.; Agaimy, A.; Dickson, B.C.M.; Dueber, J.C.; Eberhart, C.G.; Gagan, J.; Hartmann, A.; Khararjian, A.M.; London, N.R.; MacMillan, C.M.; et al. DEK-AFF2 Carcinoma of the Sinonasal Region and Skull Base. Am. J. Surg. Pathol. 2021, 45, 1682–1693. [Google Scholar] [CrossRef]
  24. Turri-Zanoni, M.; Gravante, G.; Castelnuovo, P. Molecular Biomarkers in Sinonasal Cancers: New Frontiers in Diagnosis and Treatment. Curr. Oncol. Rep. 2022, 24, 55–67. [Google Scholar] [CrossRef] [PubMed]
  25. Chang, B.; Sheng, W.; Wang, L.; Zhu, X.; Tan, C.; Ni, S.; Weng, W.; Huang, D.; Wang, J. SWI/SNF Complex-deficient Undifferentiated Carcinoma of the Gastrointestinal Tract. Am. J. Surg. Pathol. 2021, 46, 889–906. [Google Scholar] [CrossRef]
  26. Agaimy, A. Abbas SWI/SNF-deficient Sinonasal Carcinomas. Adv. Anat. Pathol. 2022, 30, 95–103. [Google Scholar] [CrossRef]
  27. Skálová, A.; Taheri, T.; Bradová, M.; Vaněček, T.; Franchi, A.; Slouka, D.; Kostlivý, T.; de Rezende, G.; Michálek, J.; Klubíčková, N.; et al. SMARCB1-deficient sinonasal adenocarcinoma: a rare variant of SWI/SNF-deficient malignancy often misclassified as high-grade non-intestinal-type sinonasal adenocarcinoma or myoepithelial carcinoma. Virchows Arch. 2023, 485, 245–256. [Google Scholar] [CrossRef]
  28. Agaimy, A.; Hartmann, A.; Antonescu, C.R.; Chiosea, S.I.; El-Mofty, S.K.; Geddert, H.; Iro, H.; Lewis, J.S.J.; Märkl, B.; Mills, S.E.; et al. SMARCB1 (INI-1)-deficient Sinonasal Carcinoma. Am. J. Surg. Pathol. 2017, 41, 458–471. [Google Scholar] [CrossRef]
  29. Parker, N.A.; Al-Obaidi, A.; Deutsch, J.M. SMARCB1/INI1-deficient tumors of adulthood. F1000Research 2020, 9, 662. [Google Scholar] [CrossRef]
  30. Caltabiano, R.; Magro, G.; Polizzi, A.; Praticò, A.D.; Ortensi, A.; D’orazi, V.; Panunzi, A.; Milone, P.; Maiolino, L.; Nicita, F.; et al. A mosaic pattern of INI1/SMARCB1 protein expression distinguishes Schwannomatosis and NF2-associated peripheral schwannomas from solitary peripheral schwannomas and NF2-associated vestibular schwannomas. Child's Nerv. Syst. 2017, 33, 933–940. [Google Scholar] [CrossRef]
  31. Esposito, A.; Stucchi, E.; Baronchelli, M.; Di Mauro, P.; Ferrari, M.; Lorini, L.; Gurizzan, C.; London, N.R.J.; Hermsen, M.; Lechner, M.; et al. Molecular Basis and Rationale for the Use of Targeted Agents and Immunotherapy in Sinonasal Cancers. J. Clin. Med. 2022, 11, 6787. [Google Scholar] [CrossRef] [PubMed]
  32. Ferrari, M.; Taboni, S.; Carobbio, A.L.C.; Emanuelli, E.; Maroldi, R.; Bossi, P.; Nicolai, P. Sinonasal Squamous Cell Carcinoma, a Narrative Reappraisal of the Current Evidence. Cancers 2021, 13, 2835. [Google Scholar] [CrossRef]
  33. Ayyanar, P.; Mishra, P.; Preetam, C.; Adhya, A.K. SMARCB1/INI1 Deficient Sino-Nasal Carcinoma: Extending the Histomorphological Features. Head Neck Pathol. 2021, 15, 555–565. [Google Scholar] [CrossRef] [PubMed]
  34. Agaimy, A.; Weichert, W. SMARCA4-deficient Sinonasal Carcinoma. Head Neck Pathol. 2017, 11, 541–545. [Google Scholar] [CrossRef] [PubMed]
  35. Agaimy, A.; Weichert, W. SMARCA4-deficient Sinonasal Carcinoma. Head Neck Pathol. 2017, 11, 541–545. [Google Scholar] [CrossRef] [PubMed]
  36. Kohashi, K.; Oda, Y. Oncogenic roles of SMARCB1/INI1 and its deficient tumors. Cancer Sci. 2017, 108, 547–552. [Google Scholar] [CrossRef]
  37. Agaimy, A.; Jain, D.; Uddin, N.; Rooper, L.M.; Bishop, J.A. SMARCA4-deficient Sinonasal Carcinoma. Am. J. Surg. Pathol. 2020, 44, 703–710. [Google Scholar] [CrossRef]
  38. Agaimy, A.; Franchi, A.; Lund, V.J.; Skálová, A.; Bishop, J.A.; Triantafyllou, A.; Andreasen, S.; Gnepp, D.R.; Hellquist, H.; Thompson, L.D.; et al. Sinonasal Undifferentiated Carcinoma (SNUC): From an Entity to Morphologic Pattern and Back Again-A Historical Perspective. Adv. Anat. Pathol. 2020, 27, 51–60. [Google Scholar] [CrossRef]
  39. Alzumaili, B.; Sadow, P.M. IDH2-Mutated Sinonasal Tumors: A Review. Adv. Anat. Pathol. 2022, 30, 104–111. [Google Scholar] [CrossRef]
  40. Turri-Zanoni, M.; Gravante, G.; Castelnuovo, P. Molecular Biomarkers in Sinonasal Cancers: New Frontiers in Diagnosis and Treatment. Curr. Oncol. Rep. 2022, 24, 55–67. [Google Scholar] [CrossRef]
  41. Hongo, T.; Yamamoto, H.; Jiromaru, R.; Yasumatsu, R.; Kuga, R.; Nozaki, Y.; Hashimoto, K.; Matsuo, M.; Wakasaki, T.; Tamae, A.; et al. PD-L1 expression, tumor-infiltrating lymphocytes, mismatch repair deficiency, EGFR alteration and HPV infection in sinonasal squamous cell carcinoma. Mod. Pathol. 2021, 34, 1966–1978. [Google Scholar] [CrossRef] [PubMed]
Preprints 116512 g001
Figure 1. Squamous cell carcinomas: (A) CT scan of a KSCC originating in the maxillary sinus, occupying the nasal cavity and ethmoid cells. (B) Macroscopic image of a maxillectomy with orbital exenteration of KSCC. (C) HE 100x photomicrograph of SMARCA4-deficient sinonasal carcinoma. (D) HE 100x of NKSCC with high-grade features. (E) HE 100x of SCC with high-grade features. (F) HE 100x of SMARCB1-deficient sinonasal carcinoma.
Figure 1. Squamous cell carcinomas: (A) CT scan of a KSCC originating in the maxillary sinus, occupying the nasal cavity and ethmoid cells. (B) Macroscopic image of a maxillectomy with orbital exenteration of KSCC. (C) HE 100x photomicrograph of SMARCA4-deficient sinonasal carcinoma. (D) HE 100x of NKSCC with high-grade features. (E) HE 100x of SCC with high-grade features. (F) HE 100x of SMARCB1-deficient sinonasal carcinoma.
Preprints 116512 g001
Preprints 116512 g002
Figure 2. Partial loss of SWI/SNF complex in sinonasal SCC. Photomicrographs with hematoxylin and eosin-stained sections of (A) Sinonasal Non-keratinizing squamous cell carcinoma (400x), (B) Sinonasal Keratinizing squamous cell carcinoma (400x), (C) Immunohistochemical mosaic expression of SMARCB1 in NKSSC (400x), (D) Immunohistochemical mosaic expression of SMARCA4 in NKSSC (400x), (E) Immunohistochemical mosaic expression of SMARCB1 in KSSC (400x), (F) Immunohistochemical mosaic expression of SMARCA4 in KSSC, (G) SMARCB1-deficient sinonasal carcinoma, (H) SMARCA4-deficient sinonasal carcinoma.
Figure 2. Partial loss of SWI/SNF complex in sinonasal SCC. Photomicrographs with hematoxylin and eosin-stained sections of (A) Sinonasal Non-keratinizing squamous cell carcinoma (400x), (B) Sinonasal Keratinizing squamous cell carcinoma (400x), (C) Immunohistochemical mosaic expression of SMARCB1 in NKSSC (400x), (D) Immunohistochemical mosaic expression of SMARCA4 in NKSSC (400x), (E) Immunohistochemical mosaic expression of SMARCB1 in KSSC (400x), (F) Immunohistochemical mosaic expression of SMARCA4 in KSSC, (G) SMARCB1-deficient sinonasal carcinoma, (H) SMARCA4-deficient sinonasal carcinoma.
Preprints 116512 g002
Preprints 116512 g003
Figure 3. Survival analysis (Kaplan-Meier). (A) SMARCB1 mosaic expression in NKSCC, (B) SMARCA4 mosaic expression in NKSCC, (C) SMARCB1 mosaic expression in KSCC, (D) SMARCA4 mosaic expression in KSCC.
Figure 3. Survival analysis (Kaplan-Meier). (A) SMARCB1 mosaic expression in NKSCC, (B) SMARCA4 mosaic expression in NKSCC, (C) SMARCB1 mosaic expression in KSCC, (D) SMARCA4 mosaic expression in KSCC.
Preprints 116512 g003
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.
Copyright: This open access article is published under a Creative Commons CC BY 4.0 license, which permit the free download, distribution, and reuse, provided that the author and preprint are cited in any reuse.
Prerpints.org logo

Preprints.org is a free preprint server supported by MDPI in Basel, Switzerland.

facebook logotwitter logolinkedin logo
MDPI Initiatives
Important Links
Subscribe

Disclaimer

Terms of Use

Privacy Policy

© 2024 MDPI (Basel, Switzerland) unless otherwise stated